[Module of hypercoagulation as a biomarker for estimation of hemostasis risk factor of thrombosis, determination of an individual antiaggregant dose and the way of its use in patients with arterial hypertension].
12 patients with stage II arterial hypertantion have been administered a complex therapy including antihypertensive, hypocholesterolemic (statines), and antiagregant (aspirin, acelisin) agents as a preventive maintenance of vascular complications (stroke, myocardial infarction). Optimization of individual treatment was established by controlling parameters of the integrated indicator of the coagulation cascade of whole blood. This indicator is called the coagulation module (CM). In a clinical practice this biomarker favours qualitative assessment of disorders of the coagulation potential and degree of its dysfunction. Patients having a high risk factor (CM+VI-VIII degree) have began their treatment with intramuscular administration of acelisin in individual doses within 4-6 days.
Tolstopiatov
S M
SM
D000368:Aged; D015415:Biomarkers / Q000097:blood; D001777:Blood Coagulation / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006487:Hemostasis / Q000187:drug effects / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D013927:Thrombosis / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D016896:Treatment Outcome
D015415:Biomarkers; D005343:Fibrinolytic Agents